Immunome Inc IMNM is surging Tuesday morning after the company reported the pre-clinical testing results of its antibody cocktail.
Immunome announced that its three-antibody cocktail, IMM-BCP-01, demonstrated neutralizing activity against the SARS-CoV-2 Delta variant. The company also said that IMM-BCP-01 showed in-vitro activity via non-neutralizing mechanisms.
“IMM-BCP-01’s ability to maintain neutralizing activity against emerging SARS-CoV-2 variants, including the Delta variant, potentially positions our drug candidate as a long-term solution to the changing threat posed by COVID-19," said Purnanand Sarma, president and CEO of Immunome.
Amid the recent resurgence of COVID-19 variants, the company said it plans to explore opportunities to expedite the development of its potential therapeutic.
Price Action: Immunome has traded as high as $63.78 and as low as $9.27 over a 52-week period.
At last check Tuesday, the stock was up 39.40% at $23.20.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
